The 2026–2027 Patent Cliff: Pharmacy’s Next Inflection Point
Over the next 24 months, one of the most under-discussed shifts in healthcare will quietly unfold. You’ve probably heard the phrase…
Foundayo (orforglipron): A New Era for Oral GLP-1 Therapy
The FDA’s approval of Eli Lilly’s once-daily oral GLP-1 receptor agonist marks a pivotal shift in how obesity may be treated. A…
After Two Decades of Silence, A Lyme Vaccine Is Finally Within Reach
For 24 years, Americans have had no vaccine against Lyme disease. That may be about to change, and pharmacists will be among the first people…
Beyond Infection Control: The Lasting Microbiome Impact of Antibiotics
Antibiotics can have long-lasting gut effects. Antibiotics have revolutionized modern medicine, saving countless lives. But new research…
Alzheimer’s Therapy Turns a Corner: The Rise of Amyloid-Targeting Antibodies
Promising new treatments for early Alzheimer’s disease. The Alzheimer’s Treatment Playbook Is Finally Changing Over the past few years, we’ve…